Steglatro

Physical Activity, Type 2 Diabetes, Diet

Treatment

4 FDA approvals

20 Active Studies for Steglatro

What is Steglatro

Ertugliflozin

The Generic name of this drug

Treatment Summary

Ertugliflozin is a medication used to treat type 2 diabetes. It works by blocking a protein in the body that helps to reabsorb glucose from the kidneys. This drug was approved by the FDA in 2017 and is available as a standalone treatment or in combination with other diabetes medications such as sitagliptin or metformin hydrochloride.

Steglatro

is the brand name

image of different drug pills on a surface

Steglatro Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Steglatro

Ertugliflozin

2017

13

Approved as Treatment by the FDA

Ertugliflozin, also known as Steglatro, is approved by the FDA for 4 uses like Type 2 Diabetes Mellitus and Type 2 Diabetes .

Type 2 Diabetes Mellitus

Used in combination with other therapies

Type 2 Diabetes

Used in combination with other therapies

Physical Activity

Used in combination with other therapies

Diet

Used in combination with other therapies

Effectiveness

How Steglatro Affects Patients

Ertugliflozin works by causing the body to excrete more glucose in the urine. This results in a negative balance and increased urination. As a result, this diabetes drug has been found to help lower body weight and blood pressure in those with diabetes.

How Steglatro works in the body

Ertugliflozin helps to reduce blood sugar levels by blocking a protein that normally reabsorbs glucose from the urine. This causes more glucose to be excreted in the urine, which lowers the amount of glucose in the blood. As a result, it reduces hyperglycemia without needing to produce more insulin.

When to interrupt dosage

The suggested dose of Steglatro is contingent upon the diagnosed affliction, including Type 2 Diabetes, Diet and Physical Activity. The magnitude of dosage varies, in line with the administration technique (e.g. Tablet, film coated - Oral or Oral) indicated in the table below.

Condition

Dosage

Administration

Physical Activity

, 5.0 mg, 15.0 mg, 2.5 mg, 7.5 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet

Type 2 Diabetes

, 5.0 mg, 15.0 mg, 2.5 mg, 7.5 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet

Diet

, 5.0 mg, 15.0 mg, 2.5 mg, 7.5 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet - Oral, Tablet

Warnings

Steglatro has two contraindications and should not be incorporated with the disorders listed in the following table.

Steglatro Contraindications

Condition

Risk Level

Notes

Dialysis therapy

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Ertugliflozin may interact with Pulse Frequency

There are 20 known major drug interactions with Steglatro.

Common Steglatro Drug Interactions

Drug Name

Risk Level

Description

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Ertugliflozin.

Belinostat

Major

The metabolism of Belinostat can be decreased when combined with Ertugliflozin.

Binimetinib

Major

The metabolism of Binimetinib can be decreased when combined with Ertugliflozin.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Ertugliflozin.

Etoposide

Major

The metabolism of Etoposide can be decreased when combined with Ertugliflozin.

Steglatro Toxicity & Overdose Risk

Ertugliflozin has been found to be generally safe, with few reported side effects. However, there has been an increased incidence of adrenal medullary pheochromocytoma, which may be caused by the drug's effects on calcium levels. There have been no reports of mutagenic activity or fertility problems associated with use of the drug.

image of a doctor in a lab doing drug, clinical research

Steglatro Novel Uses: Which Conditions Have a Clinical Trial Featuring Steglatro?

196 active clinical trials are currently being conducted to assess the effectiveness of Steglatro in managing Type 2 Diabetes, Physical Activity and Dietary modifications.

Condition

Clinical Trials

Trial Phases

Physical Activity

24 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Type 2 Diabetes

167 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Steglatro Reviews: What are patients saying about Steglatro?

4

Patient Review

3/16/2019

Steglatro for Type 2 Diabetes Mellitus

This drug has already lowered my sugar levels by 50 points and I've only just started using it. If it keeps up this good work, it'll be a great help to me.

3

Patient Review

5/7/2020

Steglatro for Type 2 Diabetes Mellitus

I've been on steglatro for just over two weeks now, and I'm not seeing the results I'd hoped for. My sugar hasn't dropped much, which is concerning. Additionally, I've developed a pain in my neck that's worrying me. Not sure if I'll continue with this medication or not.

2.3

Patient Review

2/3/2019

Steglatro for Type 2 Diabetes Mellitus

I started using this medication four months ago and saw great results the first month. However, since then I've been dealing with vaginal itchiness and a yeast infection that won't go away no matter what medicine I take. Additionally, I've had problems with constipation. Overall, it's not worth it to me and I'm going back to my previous medication.

1.7

Patient Review

8/21/2018

Steglatro for Type 2 Diabetes Mellitus

I got a nasty yeast infection within a week of starting to take this medication. My blood sugar levels didn't improve either. I can only hope that it works better for other people than it did for me.

1.7

Patient Review

10/1/2019

Steglatro for Type 2 Diabetes Mellitus

I had some really unpleasant side effects after taking this medication for just two weeks. I'm glad I stopped when I did, and it seems like the symptoms have mostly dissipated now.

1

Patient Review

12/14/2021

Steglatro for Type 2 Diabetes Mellitus

This drug unfortunately caused me a lot of dehydration and an increased heart rate.

1

Patient Review

1/29/2022

Steglatro for Type 2 Diabetes Mellitus

I experienced literally every single side effect this treatment came with, and it didn't even help lower my sugar levels. I'm really struggling, but my doctor called me this morning to check in. She was very understanding and called in a new prescription for me that should be more effective.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about steglatro

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is metformin a Steglatro?

"SEGLUROMET is a prescription medicine that contains 2 drugs - ertugliflozin (STEGLATRO ®) and metformin hydrochloride. It is used to improve blood sugar levels in adults with type 2 diabetes, when used with diet and exercise."

Answered by AI

What side effects does Steglatro have?

"The side effects of Steglatro may include: back pain, headache, increased thirst, producing more urine or needing to urinate more often than usual, stuffy or runny nose, urinary tract infection (UTI), vaginal itchiness, weight loss."

Answered by AI

Are Jardiance and Steglatro the same?

"No, Steglatro is not the same as Jardiance. However, they are very similar drugs. They both belong to the drug class sodium glucose cotransporter 2 (SGLT2) inhibitors. Steglatro contains ertugliflozin as the active drug while Jardiance contains empagliflozin."

Answered by AI

What is the drug Steglatro used for?

"STEGLATRO is a prescription pill used in adults with type 2 diabetes to improve blood sugar (glucose) control along with diet and exercise. STEGLATRO is not for people with type 1 diabetes as it may increase the risk of diabetic ketoacidosis in these people."

Answered by AI

Clinical Trials for Steglatro

Image of Centre EPIC in Montreal, Canada.

Maple Syrup for Endurance Cycling Performance

18 - 45
Male
Montreal, Canada

The goal of this clinical trial is to learn whether maple syrup can be used as a natural carbohydrate source to help trained male cyclists perform better during long-duration cycling. The study also aims to learn how different amounts of maple syrup affect energy use in the body, stomach comfort, and feelings of effort and fatigue. The main questions the study aims to answer are: * Does consuming more carbohydrate from maple syrup help participants finish a 20-kilometer cycling time trial faster? * How do different amounts of maple syrup change how the body uses carbohydrates and fats during long exercise? * Are higher amounts of maple syrup easy for participants to tolerate without stomach problems? Researchers will compare four drinks: 1. A placebo drink (a look-alike drink with no calories), 2. A drink that provides 60 grams of carbohydrate per hour, 3. A drink that provides 90 grams per hour, and 4. A drink that provides 120 grams per hour. They will compare these drinks to see whether higher carbohydrate amounts lead to better cycling performance and how each dose affects comfort and metabolism. Participants will: * Attend a screening visit that includes a health check and a glucose tolerance test. * Complete a fitness test to measure their aerobic capacity and practice the cycling tests used in the study. * Take part in four separate exercise sessions in random order. Each session includes: * Drinking one of the four study beverages during 2 hours of steady cycling, * Completing two short, all-out 6-second sprints during the ride, * Completing a 20-kilometer cycling time trial as fast as possible, * Reporting stomach symptoms and perceptions of effort, * Providing breath, blood, urine, and sweat samples so researchers can measure how their body uses fuel. All drinks will look, taste, and smell similar so participants cannot tell which one they are receiving. Meals before each session will be provided to keep conditions the same across visits. This study may help athletes and active people choose natural carbohydrate sources that support both performance and comfort during long endurance exercise. The findings may also guide future research on the use of maple syrup as a sports nutrition option.

Waitlist Available
Paid Trial

Centre EPIC

Jonathan Tremblay, PhD

Mitacs

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Faculty of Health Sciences in Winnipeg, Canada.

Saskatoon Berries for Type 2 Diabetes

18 - 74
All Sexes
Winnipeg, Canada

Diabetes becomes epidemic in worldwide countries. Diabetes Canada indicated that 30% of adults in Manitoba are diabetes or prediabetes. Nine out of ten diabetic patients are type 2 diabetes (T2D). T2D is characterized by insulin resistance and obesity. Uncontrolled diabetes leads to serious consequences including heart attack, stroke, chronic renal failure, liver failure, blindness and low limb amputation. Most of hypoglycemic medications have certain side effects. Natural foods or nutraceuticals with hypoglycemic potential are expected to provide a safer management for diabetic patients. Saskatoon berry is a popular fruit in Canadian Prairie and Northern states in USA. Previous studies in the investigator's group demonstrated Saskatoon berry (SB) powder attenuated hyperglycemia, hyperlipidemia, insulin resistance, inflammation, liver steatosis and gut dysbiosis in diet-induced insulin resistant mice, a model for T2D. The findings of the glucose and lipid lowering or liver protective effects of SB powder have been supported by another group in Australia in high fat fed rats. Preliminary studies by the investigators in 20 healthy subjects demonstrated that dried whole SB (40 g/day for 10 weeks) significantly reduced fasting plasma glucose, total and LDL-cholesterol, systolic blood pressure, and increased plasma glucagon-like peptide compared to baseline, which was associated with increased intake of total fiber and decreased intake of saturated fat. The changes in metabolic and vascular variables significantly correlated with the alterations in gut microbiota The combination of findings suggest that SB is good candidate of prebiotic functional food as a supplemental remedy for reducing the risk for metabolic syndrome and preventing or managing T2D. The effect of Saskatoon berry and its products on metabolic disorders have not been studied in diabetic subjects. The investigators propose to examine the effects of oral administration of freeze-dried whole SB on glucose metabolism, insulin resistance and gut microbiota in untreated prediabetes and new type 2 diabetic patients compared to a control dried fruit in a randomized controlled trial.

Waitlist Available
Dietary Supplement

Faculty of Health Sciences

Have you considered Steglatro clinical trials?

We made a collection of clinical trials featuring Steglatro, we think they might fit your search criteria.
Go to Trials
Image of Central Research Associates - Flourish - PPDS in Birmingham, United States.

CX11 for Type 2 Diabetes

18 - 75
All Sexes
Birmingham, AL

This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.

Phase 2
Waitlist Available

Central Research Associates - Flourish - PPDS (+29 Sites)

Corxel Pharmaceuticals

Have you considered Steglatro clinical trials?

We made a collection of clinical trials featuring Steglatro, we think they might fit your search criteria.
Go to Trials
Image of NYU Langone Health in New York, United States.

Adaptive Dietary Intervention for Type 2 Diabetes

18+
All Sexes
New York, NY

The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range \[TIR\] from baseline) will continue with the CGM alone during weeks 4-12 ("CGM Alone"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM ("CGM-GEM").

Waitlist Available
Has No Placebo

NYU Langone Health

Yaguang Zheng, PhD, RN

Image of KPNC Division of Research in Pleasanton, United States.

MetSense Risk Flag for Type 2 Diabetes

18+
All Sexes
Pleasanton, CA

People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.

Waitlist Available
Has No Placebo

KPNC Division of Research

Esti Iturralde, PhD

Have you considered Steglatro clinical trials?

We made a collection of clinical trials featuring Steglatro, we think they might fit your search criteria.
Go to Trials